stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Current ratio
Legend Biotech Corporation Sponsored ADR's current ratio at the end of the quarter to 30 June 2026 was 3.0×, up 1.1× from fiscal 2025 (2.0×). Over the past ten years it has ranged from 1.6× (fiscal 2019) to 6.9× (fiscal 2023); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 5.0× and in line with the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.0× | (57.61%) |
| FY2024 | 4.6× | (33.20%) |
| FY2023 | 6.9× | 87.51% |
| FY2022 | 3.7× | (10.94%) |
| FY2021 | 4.1× | 12.66% |
| FY2020 | 3.7× | 126.93% |
| FY2019 | 1.6× | (21.08%) |
| FY2018 | 2.1× | (53.76%) |
| FY2017 | 4.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.0× | 43.00% |
| Mar 2026 | 2.1× | 8.53% |
| Dec 2025 | 2.0× | (31.59%) |
| Sep 2025 | 2.9× | (39.15%) |
| 23 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 30.0× |
| CRSP CRISPR Therapeutics AG compare | 16.2× |
| RLAY Relay Therapeutics, Inc. compare | 14.6× |
| COGT Cogent Biosciences, Inc. compare | 13.6× |
| EWTX Edgewise Therapeutics, Inc. compare | 12.3× |
| ERAS Erasca, Inc. compare | 8.3× |
| DFTX Definium Therapeutics, Inc. compare | 6.9× |
| LEGN Legend Biotech Corporation Sponsored ADR | 3.0× |
| TVTX Travere Therapeutics, Inc. compare | 3.0× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement